BioFilm Control

Background

BioFilm Control is a Biotechnology R&D company, formed in 2004, which has developed one-of-a-kind proprietary technology using magnetisable microbeads, protected by 7 patents and 9 trademarks. This technology detects the biofilm behaviour of microorganisms and was automated in 2009. This is the only “biofilm” technology in Medical Analysis Laboratories (Public or Private institutions).

BioFilm Control markets BioFilm Ring Test® and Antibiofilmogram® kits in 96-well plate format for research use only. The Antibiofilmogram® kits study the susceptibility of bacteria to antibiotics, both in planktonic and biofilm populations. Three panels of 11 antibiotics are available, defined for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Clinical protocols are under way and the first MD-IVD versions with CE marking are scheduled for 2017.
The company also operates its biofilm expertise under R&D (pharmaceutical industry – human health and veterinary applications-, cosmetics industry, food, hygiene, etc).

Beyond microbiology, BioFilm Control can boast the performance of its original technology using magnetisable microbeads in other fields:
– In Immunohaematology to develop blood or total serum diagnosis tests, in less than 45 minutes with no purification steps (detection of malaria parasites, detection of cancerous cells, etc) ;
– In Enzymology, with very high sensitivity for enzymatic mapping (lyases, proteases, lipase, nucleases…) or to characterise enzymatic activities on soluble polymers (with real-time kinetics monitoring of the same sample).

BioFilm Control currently boasts manpower of 10 people working in premises of 400m², 90m² of which dedicated to a P2 laboratory. The team is made up of 2 directors-researchers, one Project Manager, one administrative assistant and 6 technicians. BioFilm Control is also backed by a Scientific Committee made up of:  Prof. Kaplan, Ph.D. American University, Washington (inventor of the first antibiofilm agent, Dispersin B),  Pr McArthur, M.D., Ph.D., University of Missouri, Kansas City (expert on Mycobacterium tuberculosis, on HIV, on Diagnostic tests), Prof. Tulkens, Univ. Catholique  Louvain (one of the founders of EUCAST), Dr Jehl, CHU Strasbourg (Chairman of the French Antibiogram Committee), Dr Laurent, AP-HP Lyon (reference for Bone & Joint Infections), Prof. Lavigne and Prof. Sotto, CHU Nîmes (Diabetic Foot reference)…

Read more

Ongoing Antibiofilmogram® validation for clinical diagnosis

07/04/2016

Biological validation : A publication in JCM describes the use of the BioFilm Ring Test as a routine analysis method of P. aeruginosa biofilms in case of Cystic Fibrosis. http://jcm.asm.org/content/54/3/657.long Clinical Validation : Lauching of 2 clinical trials,  soon followed by a third one. A clinical trial

actus

26th ECCMID Congress , April 9 to 12 , AMSTERDAM , THE NETHERLANDS

22/02/2016

BioFilm Control will attend this event and will present a poster showing in particular the use of Antibiofilmogram® test on clinical strains of P. aeruginosa from cystic fibrosis patients. It is shown that some antibiotics conventionally used induce in vitro adhesion of naturally non-adherent strains.

eccmid_-2016-new-small.png__555x416_q85_crop_subsampling-2

Management team

Thierry Bernardi

Dirigeant & fondateur

Thierry BERNARDI is the founder of BioFilm Control as well as the inventor of the BioFilm Ring Test®. He has co-authored 8 peer reviewed publications and 7 patent applications using the BioFilm Ring Test® technology. Prior to founding BioFilm Control, he held several technical, general management and business development positions intechnical, general management and business development positions in start-ups and multinational companies. In 1991, he earned his Pharm.D from the University of Montpellier (France).

Christian Provot

Dirigeant & fondateur

Christian PROVOT, R&D Director (CSO)
With a PhD in Cellular and Molecular Biology, Christian Provot has 22 years of experience in R&D applied to manual or HTS diagnostics in healthcare, cosmetics, pharmacy and the food sectors using molecular and immunological biology methods (ELISA with optical, fluorescence or luminometric detection).
He joined BioFilm Control in June 2013.

Who we are

BioFilm Control is a 12 persons team :

image

R&D technicians

image

Ph.D. and 1 Pharm.D.

image

administrative assistant

image

Ph.D. students in biology

Scientific Advisory Board

image image image

Prof. McArthur

Prof. McArthur

Professor

Carole McARTHUR, M.D., Ph.D., is a physician and scientist, Professor at the University of Missouri in Kansas City. She has extensive experience in both the academic and private sectors in the development of diagnostic systems for the detection of a wide range of substances. These range from microorganisms, fungi, protozoa to proteins, peptides and many small molecules including therapeutic and abused drugs such as steroids , barbiturates, amphetamines and PCP. Her current research focuses on HIV and Tuberculosis Point Of Care (POC) diagnostics for drug resistance in Africa.

image image image

Dr Jehl

Dr Jehl

Doctor

François JEHL, Pharm.D., is Lecturer of University and Hospital Practitioner (MCU-PH) at the University Hospital of Strasbourg. Coordinator of the Antimicrobial Committee of the French Society of Microbiology (SFM), he is the author of more than 200 publications on antibiotics in vitro activity, pharmacokinetics, tissue distribution, PK / PD, experimental infections. Currently, he is studying the impact of antibiotics on the formation or prevention of biofilm in vitro by Pseudomonas aeruginosa isolated from pulmonary infections of patients with cystic fibrosis.

image image image

Prof. Tulkens

Prof. Tulkens

Professor

Paul M. TULKENS, M.D., Ph.D., is currently Emeritus and Invited Professor at the Faculties of Medicine and of Pharmacy & Biomedical Sciences of the Health Science Sector of the Université Catholique de Louvain. He is also the representative of the International Society for Chemotherapy (ISC) at EUCAST. Among his various fields of research, he worked on pharmacodynamics and pharmacokinetics of anti-infective drugs (in vitro models and clinical trials), on the discovery and development of new antibiotics. He is strongly involved in the promotion of proper antibiotic usage (through guidelines and public actions). He is a member of the editorial board of different peer-reviewed journals.

micro Over 150 m2 of laboratories:

1 P2 laboratory of 90 m2

1 production-dedicated laboratory

1 immunohaematology laboratory

Robotic platform

BioFilm Control runs its Hamilton Robotics platform dedicated to :

  • microplate preparation (antibiotics, compounds, etc)
  • inoculation of bacterial suspensions
  • incubation and reading of microplates

Up to 4,000 tests per day in sterile conditions (microbiological safety cabinet, specially designed for the platform)